Recent innovations in the management of hepatocellular cancer in the setting of liver transplantation: preface
Preface

Recent innovations in the management of hepatocellular cancer in the setting of liver transplantation: preface

It is our great pleasure to introduce the Focused Issue entitled: “Recent Innovations in the Management of Hepatocellular Cancer in the Setting of Liver Transplantation”. Liver transplantation (LT) is the unique curative treatment for both Hepatocellular carcinoma (HCC) and liver cirrhosis. Twenty years have passed since the Milan criteria indicated how to select the best HCC candidates for LT (1). In the present focused issue we have underlined all the most recent evolutions in the field of LT for HCC. Centers all around the world have been involved to discuss these innovations. We asked Dr. Finkenstedt (Austria) to explain “when is liver transplantation oncologically futile?” (2). Dr. Vitale (Italy) reported his research on the “selection of patients with hepatocellular cancer: a difficult balancing between priority, utility and benefit” (3). Dr. Oldani (Switzerland) analyzed the “enlarged selection criteria for hepatocellular cancer: is the upper limit needed?” (4). Another important analyzed aspect was the role biomarkers as prognostic factors for selecting HCC patients waiting for LT. This issue had two important contributions in this field, namely the study by Prof. Halazun (United States) focused on the “Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation” (5) and the study by Dr. Lai (Italy) with “The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution” (6). Apart the selection criteria, the present issue also stressed the preoperative role of locoregional treatments as bridge or downstaging approached. Dr. Coletta (Italy) answered to the question if “Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same?” (7). Dr. Lucatelli (Italy) stressed the new concept of “single injection dual phase-CBCT technique ameliorates results of trans-arterial chemoembolization for hepatocellular cancer” (8). In the field of innovation, we reported the “Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantationa world review” (9). Lastly, Dr. Tsochatzis (United Kingdom) presented a study entitled “Downstaging for hepatocellular cancer: harm or benefit?” (10). Dr. Pinheiro (Brazil) focused on his attention on “Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?” (11). The innovative aspect of perfusion machines was investigated by Dr. Ghinolfi (Italy), who analyzed the “perfusion machines and hepatocellular carcinoma: a good match between a marginal organ and an advanced disease?” (12). Dr. Manzia (Italy) analyzed the immunosuppressive regiment for HCC candidates “Using a weaning immunosuppression protocol: a compromise between the risk of recurrence and the risk of rejection?” (13). Lastly, we asked to Prof. Lerut (Belgium) to analyzed the “Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?” (14).

The Focused Issue was superlatively introduced by prof. Lerut (Belgium) with his editorial “hepatocellular cancer and liver transplantation: from the tower of babel towards a uniform language” (15). We are glad that the present issue has been realized thanks to the extraordinary help of so many experts coming from several different countries all around the world. We thank all of them for their great effort and contributions.


Acknowledgements

None.


References

  1. Levi Sandri GB, Lai Q. Twenty years after: from Milan criteria to a “blended” approach. Transl Gastroenterol Hepatol 2017;2:62. [Crossref] [PubMed]
  2. Viveiros A, Zoller H, Finkenstedt A. Hepatocellular carcinoma: when is liver transplantation oncologically futile? Transl Gastroenterol Hepatol 2017;2:63. [Crossref] [PubMed]
  3. Vitale A, Lai Q. Selection of patients with hepatocellular cancer: a difficult balancing between equity, utility, and benefit. Transl Gastroenterol Hepatol 2017;2:75. [Crossref] [PubMed]
  4. Peloso A, Oldani G. Enlarged selection criteria for hepatocellular cancer: is the upper limit needed? Transl Gastroenterol Hepatol 2017;2:73. [Crossref] [PubMed]
  5. Rosenblatt RE, Tafesh ZH, Halazun KJ. Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation. Transl Gastroenterol Hepatol 2017;2:95. [Crossref] [PubMed]
  6. Lai Q, Iesari S, Melandro F, et al. The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution. Transl Gastroenterol Hepatol 2017;2:72. [Crossref] [PubMed]
  7. Coletta M, Nicolini D, Benedetti Cacciaguerra A, et al. Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same? Transl Gastroenterol Hepatol 2017;2:78. [Crossref] [PubMed]
  8. Lucatelli P, Argirò R, Bascetta S, et al. Single injection dual phase CBCT technique ameliorates results of trans-arterial chemoembolization for hepatocellular cancer. Transl Gastroenterol Hepatol 2017;2:83. [Crossref] [PubMed]
  9. Levi Sandri GB, Ettorre GM, Giannelli V, et al. Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review. Transl Gastroenterol Hepatol 2017;2:98. [Crossref] [PubMed]
  10. Bryce K, Tsochatzis EA. Downstaging for hepatocellular cancer: harm or benefit? Transl Gastroenterol Hepatol 2017;2:106. [Crossref] [PubMed]
  11. Pinheiro RS, Waisberg DR, Nacif LS, et al. Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure? Transl Gastroenterol Hepatol 2017;2:68. [Crossref] [PubMed]
  12. Ghinolfi D, Rreka E, Pezzati D, et al. Perfusion machines and hepatocellular carcinoma: a good match between a marginal organ and an advanced disease? Transl Gastroenterol Hepatol 2017;2:87. [Crossref] [PubMed]
  13. Angelico R, Parente A, Manzia TM. Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: a compromise between the risk of recurrence and the risk of rejection? Transl Gastroenterol Hepatol 2017;2:74. [Crossref] [PubMed]
  14. Lerut J, Iesari S, Foguenne M, et al. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? Transl Gastroenterol Hepatol 2017;2:80. [Crossref] [PubMed]
  15. Lerut PJ. Hepatocellualr cancer and liver transplantation: from the tower of babel towards a uniform language. Transl Gastroenterol Hepatol 2017;2:82. [Crossref] [PubMed]
Giovanni Battista Levi Sandri
Quirino Lai

Giovanni Battista Levi Sandri, MD, PhD

Division of General Surgery and Liver Transplantation, San Camillo Hospital, Rome, Italy.
(Email: gblevisandri@gmail.com)

Quirino Lai, MD

Hepato-bilio-pancreatic and Liver Transplant Unit, Department of Surgery, Umberto I Hospital, La Sapienza University, Rome, Italy.
(Email: lai.quirino@libero.it)

*These authors contributed equally to this work.

doi: 10.21037/tgh.2018.01.10

Conflicts of Interest: The authors have no conflicts of interest to declare.

doi: 10.21037/tgh.2018.01.10
Cite this article as: Levi Sandri GB, Lai Q. Recent innovations in the management of hepatocellular cancer in the setting of liver transplantation: preface. Transl Gastroenterol Hepatol 2018;3:9.